{"id":"mexidol","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL6068558","moleculeType":"Small molecule","molecularWeight":"255.27"},"aliases":["Ethylmethylhydroxypyridine Succinate"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Mexidol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:42:02.043797+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:42:08.853102+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mexidol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:42:09.581302+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068558/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:42:10.081056+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-27T23:54:59.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:12.143060+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06437626","phase":"PHASE3","title":"Efficacy and Safety of Mexidol® in Stroke Therapy","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-18","conditions":"Ischemic Stroke","enrollment":304},{"nctId":"NCT06903156","phase":"PHASE2","title":"Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2021-11-15","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":102},{"nctId":"NCT06437639","phase":"PHASE4","title":"MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2023-09-15","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":80},{"nctId":"NCT06834490","phase":"PHASE3","title":"Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-05","conditions":"Chronic Cerebral Ischemia","enrollment":318},{"nctId":"NCT06854601","phase":"PHASE3","title":"Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-07-13","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms","enrollment":333},{"nctId":"NCT06221826","phase":"PHASE4","title":"MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2023-04-17","conditions":"Ischemic Stroke, Acute","enrollment":60},{"nctId":"NCT02793687","phase":"PHASE3","title":"Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2015-03-06","conditions":"Ischemic Stroke","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"BLOOD PRESSURE INCREASED"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"DYSPNOEA"},{"count":4,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":4,"reaction":"CONTUSION"},{"count":3,"reaction":"MYOCARDIAL INFARCTION"},{"count":3,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"ABDOMINAL PAIN UPPER"},{"count":2,"reaction":"ASTHENIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL6068558"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":388,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Mexidol","genericName":"Mexidol","companyName":"Pharmasoft","companyId":"pharmasoft","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:12.143060+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}